Prostaglandin D2 generation from human lung mast cells is catalysed exclusively by cyclooxygenase-1

Al-Muhsen, 2004, The expression of stem cell factor and c-kit receptor in human asthmatic airways, Clin. Exp. Allergy, 34, 911, 10.1111/j.1365-2222.2004.01975.x Beasley, 1987, 9α, 11β-prostaglandin F2, a novel metabolite of prostaglandin D2, is a potent contractile agonist of human and guinea pig airways, J. Clin. Investig., 79, 978, 10.1172/JCI112909 Bingham, 2000, Mast-cell responses in the development of asthma, J. Allergy Clin. Immunol., 105, S527, 10.1016/S0091-6749(00)90056-3 Bochenek, 2004, Plasma 9α, 11β-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma, Thorax, 59, 459, 10.1136/thx.2003.013573 Bradding, 2006, The role of the mast cell in the pathophysiology of asthma, J. Allergy Clin. Immunol., 117, 1277, 10.1016/j.jaci.2006.02.039 Buckley, 2011, EP4 receptor as a new target for bronchodilator therapy, Thorax, 66, 1029, 10.1136/thx.2010.158568 Cahill, 2015, Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease, J. Allergy Clin. Immunol., 135, 245, 10.1016/j.jaci.2014.07.031 Chan, 1999, Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther., 290, 551 Cryer, 1998, Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs, Am. J. Med., 104, 413, 10.1016/S0002-9343(98)00091-6 Da Silva, 2006, Effect of glucocorticoids on stem cell factor expression in human asthmatic bronchi, Clin. Exp. Allergy, 36, 317, 10.1111/j.1365-2222.2006.02431.x Daham, 2011, Effects of celecoxib on major prostaglandins in asthma, Clin. Exp. Allergy, 41, 36, 10.1111/j.1365-2222.2010.03617.x Dahlén, 2004, Monitoring mast cell activation by prostaglandin D2 in vivo, Thorax, 59, 453, 10.1136/thx.2004.026641 Ennis, M., 1991. Current techniques of histamine determination: automated fluorometric assays. In: Handbook of Experimental Pharmacology 97, pp. 31–38. Feltenmark, 2008, Eoxins are pro-inflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells, Proc. Natl. Acad. Sci., 105, 680, 10.1073/pnas.0710127105 FitzGerald, 2001, The coxibs, selective inhibitors of cyclooxygenase-2, N. Eng. J. Med., 345, 433, 10.1056/NEJM200108093450607 Fruman, 1992, Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A, Proc. Natl. Acad. Sci., 189, 3686, 10.1073/pnas.89.9.3686 Gauvreau, 1999, Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation, Am. J. Respir. Crit. Care Med., 159, 31, 10.1164/ajrccm.159.1.9804030 Hamad, 2004, Aspirin-induced asthma, Drugs, 64, 2417, 10.2165/00003495-200464210-00004 Hartert, 2000, Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma, Am. J. Respir. Crit. Care Med., 162, 637, 10.1164/ajrccm.162.2.9904038 Havard, 2011, Characterization of syk expression in human lung mast cells: relationship with function, Clin. Exp. Allergy, 41, 378, 10.1111/j.1365-2222.2010.03667.x Hempel, 1994, Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes, J. Clin. Investig., 93, 391, 10.1172/JCI116971 Kay, 2013, Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells, Clin. Exp. Allergy, 43, 741, 10.1111/cea.12142 Kirkby, 2016, Systematic study of constitutive cyclooxygenase-2 expression: role of NK-κB and NFAT transcriptional pathways, Proc. Natl. Acad. Sci., 113, 434, 10.1073/pnas.1517642113 Kowalski, 2005, Association of stem cell factor expression in nasal polyp epithelial cells with aspirin sensitivity and asthma, Allergy, 60, 631, 10.1111/j.1398-9995.2005.00753.x Kowalski, 2011, Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA, Allergy, 66, 818, 10.1111/j.1398-9995.2011.02557.x Lewis, 2017, Recovery from desensitization of IgE-dependent responses in human lung mast cells, Clin. Exp. Allergy, 47, 1022, 10.1111/cea.12912 Lewis, 2013, Heterogeneity in the responses of human lung mast cells to stem cell factor, Clin. Exp. Allergy, 43, 50, 10.1111/cea.12045 Lewis, 1982, Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE, J. Immunol., 129, 1627, 10.4049/jimmunol.129.4.1627 Lowman, 1988, Human mast cell heterogeneity: histamine release from mast cells dispersed from skin, lung, adenoids, tonsils, and colon in response to IgE-dependent and nonimmunologic stimuli, J. Allergy Clin. Immunol., 81, 590, 10.1016/0091-6749(88)90199-6 Matsuoka, 2000, Prostaglandin D2 as a mediator of allergic asthma, Science, 287, 2013, 10.1126/science.287.5460.2013 Mitchell, 1994, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc. Natl. Acad. Sci., 90, 11693, 10.1073/pnas.90.24.11693 Murakami, 1995, IgE-dependent activation of cytokine-primed mouse cultured mast cells induces a delayed phase of prostaglandin D2 generation via prostaglandin endoperoxide synthase-2, J. Immunol., 155, 4445, 10.4049/jimmunol.155.9.4445 Obata, 1999, Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclooxygenase-2 in cultured human mast cells, Clin. Exp. Allergy, 29, 1129, 10.1046/j.1365-2222.1999.00604.x Ochi, 2000, Analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models, Eur. J. Pharmacol., 391, 49, 10.1016/S0014-2999(00)00051-0 O’Sullivan, 1996, Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction, J. Allergy Clin. Immunol., 98, 421, 10.1016/S0091-6749(96)70167-7 Pearce, 1983, Mast cell heterogeneity, Trends Pharmacol. Sci., 4, 165, 10.1016/0165-6147(83)90345-0 Peskar, 2003, Role of cyclooxygenase-1 and -2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection, J. Pharmacol. Exp. Ther., 305, 1233, 10.1124/jpet.103.049650 Picado, 1999, Cyclooxygenase-2 mRNA is down-expressed in nasal polyps from aspirin-sensitive asthmatics, Am. J. Respir. Crit. Care Med., 160, 291, 10.1164/ajrccm.160.1.9808048 Reddy, 1997, Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells, J. Biol. Chem., 227, 3231, 10.1074/jbc.272.6.3231 Rouzer, 2009, Cyclooxygenases: structural and functional insights, J. Lipid Res., 50, S29, 10.1194/jlr.R800042-JLR200 Steinke, 2014, Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease, J. Immunol., 193, 41, 10.4049/jimmunol.1301753 Sud’ina, 2008, Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors, Prostaglandins Leukot. Essent. Fat. Acids, 78, 99, 10.1016/j.plefa.2007.12.006 Tilley, 2001, Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes, J. Clin. Invest., 108, 15, 10.1172/JCI200113416 Ueno, 2005, Coupling between cyclooxygenases and terminal prostanoid synthases, Biochem. Biophys. Res. Comm., 338, 70, 10.1016/j.bbrc.2005.08.152 Warner, 1999, Non-steroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci., 96, 7563, 10.1073/pnas.96.13.7563 Wendell, 2014, Fatty acids, inflammation, and asthma, J. Allergy Clin. Immunol., 133, 1255, 10.1016/j.jaci.2013.12.1087 Weston, 1997, Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function, Br. J. Pharmacol., 121, 287, 10.1038/sj.bjp.0701115 Woodward, 2011, International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress, Pharmacol. Rev., 63, 471, 10.1124/pr.110.003517